… oral anticoagulants to each other in patients with atrial … a major problem when comparing
non–vitamin K antagonist oral … the effectiveness and safety between non–vitamin K antagonist …

… objectives were not comparative effectiveness or safety profiles of NOACs, or if they could
not provide data on comparative effectiveness or safety amongst NOACs in patients with AF. …

… , dabigatran vs apixaban, and rivaroxaban vs apixaban were performed following … relative
effectiveness and safety of dabigatran vs VKA among the PS-trimmed and PS-matched patient …

… comparison between rivaroxaban and apixaban versus SoC, consisting either of vitamin K
antagonists… compared with RCTs in establishing comparative effectiveness, the importance of …

… The vitamin K antagonist warfarin was the mainstay of anticoagulation before the introduction
of DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban). Unlike warfarin, DOACs …

… vitamin K antagonists (VKAs) such as warfarin. Similar patients who commenced treatment
with either dabigatran, rivaroxaban or VKAs were identified and followed-up over 1 year. …

… to vitamin K antagonists with … treatment to be associated with lower (dabigatran, apixaban)
or similar (rivaroxaban, edoxaban) bleeding risks,10 – 14 and at least equal effectiveness for …

… Recently, direct oral anticoagulants (DOACs) have rapidly replaced vitamin K antagonists
such as warfarin in the treatment of venous thromboembolism (VTE). A meta‐analysis of …

… Although vitamin K antagonists (VKAs) are highly effective in the prevention and … analysis
of the comparative effectiveness of the OACs used in France for NVAF, focused on apixaban. …

… and meta-analysis was to summarize current evidence concerning the comparative effectiveness
and safety of DOACs vs VKA in VKA-experienced real-life anticoagulant users with AF. …